Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Clinical Pharmacokinetics|May 13, 2017
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic MalignanciesSilpa Nuthalapati, Wijith Munasinghe, Vincent Giranda, et al.Cancer Chemotherapy and Pharmacology|March 2, 2017
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancerRajendar K Mittapalli, Silpa Nuthalapati, Stacie Peacock Shepherd, et al.The Journal of Pharmacology and Experimental Therapeutics|January 30, 2007
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimensQingyu Zhou, Ping Guo, Xiaomin Wang, et al.Pharmaceutical Research|March 1, 2017
Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet FormulationRajendar K Mittapalli, Silpa Nuthalapati, Alyssa E Delke DeBord, et al.Cancer Chemotherapy and Pharmacology|August 31, 2019
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patientsSilpa Nuthalapati, Sven Stodtmann, Stacie Peacock Shepherd, et al.Journal of Pharmaceutical and Biomedical Analysis|September 2, 2011
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing miceSilpa Nuthalapati, Ping Guo, Qingyu Zhou, et al.Journal of Clinical Pharmacology|April 11, 2022
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) TrialSven Stodtmann, Doerthe Eckert, Rujuta Joshi, et al.Journal of Clinical Pharmacology|April 1, 2016
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 InhibitorAhmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, et al.Clinical Pharmacokinetics|February 21, 2018
Industry Perspective on Standardizing Food-Effect Studies for New Drug DevelopmentPatrick J Marroum, Silpa Nuthalapati, Apurvasena Parikh, et al.CPT: Pharmacometrics & Systems Pharmacology|June 20, 2026
Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene DezaparvovecYuezhe Li, Partha Nandy, Eric Jordie, et al.Pageof 3